KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Enterprise Value (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Enterprise Value data on record, last reported at -$237.9 million in Q3 2025.

  • For Q3 2025, Enterprise Value fell 20.25% year-over-year to -$237.9 million; the TTM value through Dec 2025 reached -$643.0 million, up 9.09%, while the annual FY2024 figure was -$707.3 million, 57.8% up from the prior year.
  • Enterprise Value reached -$237.9 million in Q3 2025 per SRPT's latest filing, up from -$289.5 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$197.9 million in Q3 2024 and bottomed at -$2.1 billion in Q4 2021.
  • Average Enterprise Value over 5 years is -$1.4 billion, with a median of -$1.7 billion recorded in 2021.
  • Peak YoY movement for Enterprise Value: decreased 29.6% in 2022, then skyrocketed 88.59% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$2.1 billion in 2021, then rose by 5.98% to -$2.0 billion in 2022, then grew by 15.74% to -$1.7 billion in 2023, then surged by 57.8% to -$707.3 million in 2024, then surged by 66.36% to -$237.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$237.9 million in Q3 2025, -$289.5 million in Q2 2025, and -$522.8 million in Q1 2025.